Respiratory Tract Infection Treatment Market By Disease (Upper Respiratory Tract Infection, Lower Respiratory Tract Infection), By Drug Class (Antibiotics, Antiviral, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppresant, Nasal Decongestant) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025
This report on global respiratory tract infection treatment market studies various diseases and drug class. Rising prevalence of respiratory illness as per World Health Organization in 2015 three million deaths were recorded due to COPD, constantly changing climate, rising air pollution and increasing inclination to maintain personal hygiene are the drivers for the respiratory tract infection treatment market. The limiting factors related to this market are the rising incidence of antibiotic resistance and adverse events relating to the consumption of NSAIDs will hinder the growth of respiratory infection treatment market. Technological advancement in the pharmacokinetics and drug screening for adverse events will result into deep market penetration. The increasing consumption of cheap generic medicines will hinder the branded drugs market. The drugs in the pipeline are Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead) and AZD7594, PT010 (AstraZeneca) etc.
For the purpose of this study, the various diseases studied include upper respiratory tract infection, lower respiratory tract infection and others. Drug class studied for the purpose of this research include antibiotics, non-steroidal anti-inflammatory drug (NSAIDS), cough suppressant, nose decongestant and others, upper respiratory tract infection is further segmented as (common cold, sinusitis, epiglottitis and laryngitis) lower respiratory tract infection are further segmented as (flu, bronchitis, pneumonia, asthma, COPD and respiratory syncytial virus). The geographic segmentation of the global respiratory tract infection treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year. This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global respiratory tract infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global respiratory tract infection treatment market. The key players profiled in this report are Abbott Laboratories, Abbvie Inc, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Novartis AG and others.
Based on disease, the global respiratory tract infection treatment market is categorized into
- Upper respiratory tract infection
- Common cold
- Sinusitis
- Epiglottitis
- Laryngitis
- Lower respiratory tract infection
- Flu
- Bronchitis
- Pneumonia
- Chronic obstructive pulmonary disorder (COPD)
- Asthma
- Respiratory syncytial virus
Respiratory tract infection is one of the most common reason for the patients to visit the clinic or hospital. In base year 2016, Upper tract respiratory infection holds the largest market in the disease segment due to factors like, constant change in climate and rising air pollution, rising number of patients suffering with common cold as many types of viruses cause common cold, gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered face) and touching inanimate objects with contaminated hands. Lower respiratory tract infection will be the fastest growing market in the disease segment throughout the forecast period 2017-2025, chiefly due to factors such as rising number of air particulate matters which are exhumed by industrial chimneys and automobiles cause lower respiratory tract irritation and infection, on the basis of transmission it might be hospital acquired, ventilator acquired and community acquired. Technological advancement in the exact diagnosis of the causative agent in order to determine the treatment regimen for diseases like asthma, COPD and respiratory syncytial virus will be a positive factor for the fast growth of respiratory tract infection treatment market during the forecast period.
Based on drug class, the respiratory tract infection treatment market is categorized into
- Antibiotics
- Antibacterial
- Cephalosporin (Ceftriaxone, Cefotaxime)
- Penicillin (Amoxicillin, Ampicillin, Methicillin)
- B lactamase inhibitors (Sulbactam, Clavulanic acid)
- Antivirals
- Ribavarin
- Palivizumab
- Ganciclovir
- Vidarabine
- Antibacterial
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Paracetamol
- Ibuprofen
- Naproxen
- Aspirin
- Cough suppressants
- Dextromethorphan
- Pholcodine
- Benzonatate
- Diphenhydramine
- Nasal decongestants
- Phenylephrine
- Oxymetazoline
- Pseudoephedrine
- Others
Respiratory tract infection treatment are having huge application due to factors such as rising prevalence of respiratory tract infections, constant change in climate, rising air pollution and increasing cases of antibiotics resistance. In base year 2016, Non-steroidal anti-inflammatory drugs (NSAIDS) holds the largest market in the drug treatment segment chiefly due to factors such as low cost, easy availability as OTC products, immediate symptomatic relief and technological advancement in the drug formulation e.g. micronized NSAIDs have desirable pharmacodynamics activity and early excretion rate to overcome NSAIDs adverse events. Antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period of 2017-2025 mainly due to factors such as its diverse application in various respiratory tract infections, improved pharmacokinetics to specifically target the respiratory tract infection for e.g. nebulized Aztreonam formulation is more effective than Aztreonam tablets, and technological advancement in the antibiotics resulting into next generation broad spectrum antibiotics e.g. methicillin formulated with branched polyethylenimine polymer to counteract antibiotic resistant cells. Overall, the global respiratory tract infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim GmbH, Pfizer, Inc., GlaxoSmithKline plc specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the market growth for respiratory tract infection treatment.
For the purpose of this study, the global respiratory tract infection treatment market is categorized into:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
North America was observed as the largest market for respiratory tract infection treatment in the base year 2016. According to Centers for Disease Control and Prevention (CDC) American adults have 2 to 3 colds per year with underlying symptoms such as runny nose, sore throat, coughing, sneezing, headaches and body aches. The growth is attributed mainly due to large population suffering from respiratory complications and inclination to maintain personal hygiene along with favorable reimbursement scenario. Europe is expected to be the second largest market due to cool and damp weather favoring respiratory disease and regulatory approval for respiratory tract infection treatment products. Growth of Asia Pacific for respiratory tract infection treatment market is attributed by factors like rising prevalence of respiratory illness among huge population base, competitive market due to manufactures involved in respiratory tract infection treatment products, and impact of monsoon weather in the South Asian countries. However, factors such as developing health infrastructure, increasing disease awareness and increasing demand for respiratory tract infection treatment products are going to fuel the growth of respiratory tract infection treatment market in Latin America and Middle East and Africa region in the near future.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Respiratory Tract Infection Treatment Market Portraiture
2.2 Global Respiratory Tract Infection Treatment Market, by Disease, 2016 (US$ Mn)
2.3 Global Respiratory Tract Infection Treatment Market, by Drug Class, 2016 (US$ Mn)
2.4 Global Respiratory Tract Infection Treatment Market, by Geography, 2016 (Value %)
Chapter 3 Global Respiratory Tract Infection Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Constantly changing climate and rise in air particulate matter due to automobile and industrial emission
3.3 Market Restraints
3.3.1 Rising prevalence of antibiotic drug resistance
3.4 Market Opportunities
3.4.1 Rapid industrialization in the developing countries lading to increased air and water pollution will drive the respiratory tract infection treatment market in Asia Pacific
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Respiratory Tract Infection Treatment, by Key Players
Chapter 4 Global Respiratory Tract Infection Treatment Market, By Disease
4.1 Introduction
4.2 Upper respiratory tract infection
4.2.1 Common cold
4.2.2 Sinusitis
4.2.3 Epiglottitis
4.2.4 Laryngitis
4.3 Lower respiratory tract infection
4.3.1 Flu
4.3.2 Bronchitis
4.3.3 Pnuemonia
4.3.4 Chronic obstructive pulmonary disease (COPD)
4.3.5 Asthma
4.3.6 Respiratory syncytial virus
Chapter 5 Global Respiratory Tract Infection Treatment Market, By Drug Class
5.1 Market Analysis
5.2 Antibiotics
5.2.1 Antibacterial
5.2.1.1 Cephalosporin (ceftriaxone, cefotaxime)
5.2.1.2 Penicillin antibiotic (amoxicillin, ampicillin)
5.2.1.3 B lactactamase inhibitors (sulbactum,clavulanic acid)
5.2.2 Antiviral
5.2.2.1 Ribavarin
5.2.2.2 Palivizumab
5.2.2.3 Ganciclovir
5.2.2.4 Vidarabine
5.3 Non-steroidal anti-inflammatory drug (NSAIDS)
5.3.1 Paracetamol
5.3.2 Ibuprofen
5.3.3 Naproxen
5.3.4 Aspirin
5.4 Cough suppresant
5.4.1 Dextromethorphan
5.4.2 Pholcodine
5.4.3 Benzonatate
5.4.4 Diphenhydramine
5.5 Nasal decongestant
5.5.1 Phenylephrine
5.5.2 Oxymetazoline
5.5.3 Pseudoephedrine
5.6 Others
Chapter 6 Global Respiratory Tract Infection Treatment Market, By Geography
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia Pacific
6.5 Latin America
6.5.1 Brazil
6.5.2 Mexico
6.5.3 Rest of Latin America
6.6 Middle East and Africa
6.6.1 GCC
6.6.2 Rest of Middle East and Africa
Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.2 AstraZeneca
7.3 Abbvie Inc.
7.4 Boehringer Ingelheim GmbH
7.5 Cipla Pharmaceutical Company
7.6 GlaxoSmithkline plc
7.7 Pfizer Inc.
7.8 Merck & Co.
7.9 Novartis AG
7.10 F.Hoffman La Roche Ltd
7.11 Sanofi
7.12 Teva Pharmaceutical Industries Ltd.
7.13 Theravence Biopharma
7.14 Vertex Pharmaceuticals Inc.
7.15 Others
TABLE 1 Global Respiratory Tract Infection Treatment Market, By Disease, 2015-2025 (US$ Mn)
TABLE 2 Global Upper Respiratory Tract Infection Treatment Market, 2015-2025 (US$ Mn)
TABLE 3 Global Lower Respiratory Tract Infection Treatment Market, 2015-2025 (US$ Mn)
TABLE 4 Global Respiratory Tract Infection Treatment Market, By Drug Class, 2015-2025 (US$ Mn)
TABLE 5 Global Respiratory Tract Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 North America Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Middle East and Africa Respiratory Tract Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Abbott Laboratories : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 AstraZeneca : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Abbvie Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 14 Boehringer Ingelheim GmbH : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 15 Cipla Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 16 GlaxoSmithKline plc : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 17 Pfizer Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 18 Merck & Co. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 19 Novartis AG. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 20 F.Hoffman La Roche Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 21 Sanofi : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 23 Theravence Biopharma : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 24 Vertex Pharmaceuticals Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 25 Others : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
FIG. 1 Global Respiratory Tract Infection Treatment Market: Research Methodology
FIG. 2 Global Respiratory Tract Infection Treatment Market, by Disease, 2016 (US$ Mn)
FIG. 3 Global Respiratory Tract Infection Treatment Market, by Drug Class, 2016 (US$ Mn)
FIG. 4 Global Respiratory Tract Infection Treatment Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2016
FIG. 6 Market Positioning of Key Respiratory Tract Infection Treatment Vendors, 2016
FIG. 7 Common Cold Infection Market, 2015 – 2025 (US$ Mn)
FIG. 8 Sinusitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 9 Epiglottitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 10 Laryngitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 11 Flu Infection Market, 2015 – 2025 (US$ Mn)
FIG. 12 Bronchitis Infection Market, 2015 – 2025 (US$ Mn)
FIG. 13 Pneumonia Infection Market, 2015 – 2025 (US$ Mn)
FIG. 14 Chronic Obstructive Pulmonary Disease Infection Market, 2015 – 2025 (US$ Mn)
FIG. 15 Asthma Infection Market, 2015 – 2025 (US$ Mn)
FIG. 16 Respiratory Syncytial Virus Infection Market, 2015 – 2025 (US$ Mn)
FIG. 17 Antibiotics Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 18 Non-steroidal Anti-inflammatory Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 19 Cough Suppresant Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 20 Nasal Decongestant Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 21 Others Drug Class Market , 2015 – 2025 (US$ Mn)
FIG. 22 U.S. Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 23 Canada Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 24 U.K. Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 25 Germnay Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Europe Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 27 China Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 28 Japan Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Asia Pacific Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 30 Brazil Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 31 Mexico Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 32 Rest of Latin America Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 33 GCC Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 34 Rest of Middle East and Africa Respiratory Tract Infection Treatment Market , 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)